Kyriaki Tzogani

The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

Iordanis Gravanis, Kyriaki Tzogani, Paula B. van Hennik et al. · The Oncologist · 2015 · 47 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

Kyriaki Tzogani, Karri Penttilä, Johanna Lähteenvuo et al. · The Oncologist · 2020 · 47 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma

Kyriaki Tzogani, Elisabeth I Penninga, Marie Louise Schougaard Christiansen et al. · The Oncologist · 2018 · 28 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP)

Kyriaki Tzogani, Nithyanandan Nagercoil, Robert Hemmings et al. · European Journal of Dermatology · 2014 · 26 citations

Medicine, Dermatology, Pharmacotherapy +13

The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

Kyriaki Tzogani, Jorge Camarero Jiménez, Isabel García et al. · The Oncologist · 2017 · 14 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15